Statement of Ownership (sc 13g)
February 14 2019 - 4:55PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G
(Rule
13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
RULES
13d-1(b),
(c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE
13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Paratek
Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
699374302
(CUSIP Number)
December 31, 2018
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to
designate the rule pursuant to which this Schedule is filed:
☒ Rule
13d-1(b)
☐ Rule
13d-1(c)
☐ Rule
13d-1(d)
|
|
|
|
|
CUSIP No. 699374302
|
|
13G
|
|
Page
2
of 9
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSONS
Highland Capital Management, L.P.
|
2
|
|
CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP*
(a) ☐ (b) ☐
|
3
|
|
SEC USE ONLY
|
4
|
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
Delaware
|
|
|
|
|
|
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
|
5
|
|
SOLE VOTING POWER
0**
|
|
6
|
|
SHARED VOTING POWER
2,204,865**
|
|
7
|
|
SOLE DISPOSITIVE POWER
0**
|
|
8
|
|
SHARED DISPOSITIVE POWER
2,204,865**
|
|
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,204,865**
|
10
|
|
CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
☐
|
11
|
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW 9
6.9%**
|
12
|
|
TYPE OF REPORTING
PERSON*
IA, PN
|
*
|
SEE INSTRUCTIONS BEFORE FILLING OUT
|
|
|
|
|
|
CUSIP No. 699374302
|
|
13G
|
|
Page
3
of 9
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSONS
Strand Advisors, Inc.
|
2
|
|
CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP*
(a) ☐ (b) ☐
|
3
|
|
SEC USE ONLY
|
4
|
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
Delaware
|
|
|
|
|
|
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
|
5
|
|
SOLE VOTING POWER
0
|
|
6
|
|
SHARED VOTING POWER
2,204,865**
|
|
7
|
|
SOLE DISPOSITIVE POWER
0
|
|
8
|
|
SHARED DISPOSITIVE POWER
2,204,865**
|
|
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,204,865**
|
10
|
|
CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
☐
|
11
|
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW 9
6.9%**
|
12
|
|
TYPE OF REPORTING
PERSON*
HC, CO
|
*
|
SEE INSTRUCTIONS BEFORE FILLING OUT
|
|
|
|
|
|
CUSIP No. 699374302
|
|
13G
|
|
Page
4
of 9
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSONS
James D. Dondero
|
2
|
|
CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP*
(a) ☐ (b) ☐
|
3
|
|
SEC USE ONLY
|
4
|
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
United
States
|
|
|
|
|
|
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
|
5
|
|
SOLE VOTING POWER
0
|
|
6
|
|
SHARED VOTING POWER
3,153,028**
|
|
7
|
|
SOLE DISPOSITIVE POWER
0
|
|
8
|
|
SHARED DISPOSITIVE POWER
3,153,028**
|
|
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,153,028**
|
10
|
|
CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
☐
|
11
|
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW 9
9.8%**
|
12
|
|
TYPE OF REPORTING
PERSON*
HC, IN
|
*
|
SEE INSTRUCTIONS BEFORE FILLING OUT
|
SCHEDULE 13G
This Schedule 13G (this Schedule 13G) is being filed on behalf of Highland Capital Management, L.P., a Delaware limited
partnership (Highland Capital), Strand Advisors, Inc., a Delaware corporation (Strand), and James D. Dondero (collectively, the Reporting Persons).
James D. Dondero is the President of Strand. Highland Capital serves as the investment advisor to a certain private fund (the HCM
Fund). This Schedule 13G relates to the Common Stock, par value $0.001 per share (the Common Stock), of Paratek Pharmaceuticals, Inc., a Delaware corporation (the Issuer), held by (i) the HCM Fund,
(ii) certain other funds and managed accounts ultimately advised by James D. Dondero (together with the HCM Fund, the Funds) and (iii) a trust, the shares held by which James D. Dondero has the right to acquire beneficial
ownership of (the Trust).
Item 1(a)
|
Name of Issuer.
|
Paratek Pharmaceuticals, Inc.
Item 1(b)
|
Address of Issuers Principal Executive Offices.
|
75 Park Plaza
Boston,
Massachusetts 02116
Item 2(a)
|
Name of Person Filing.
|
|
(1)
|
Highland Capital Management, L.P.
|
|
(2)
|
Strand Advisors, Inc.
|
Item 2(b)
|
Address of Principal Business Office, or, if none, Residence.
|
For all Filers:
300 Crescent
Court, Suite 700
Dallas, Texas 75201
Item 2(c)
|
Citizenship or Place of Organization.
|
|
(1)
|
Highland Capital Management, L.P. is a Delaware limited partnership
|
|
(2)
|
Strand Advisors, Inc. is a Delaware corporation
|
|
(3)
|
James D. Dondero is a United States citizen
|
Item 2(d)
|
Title of Class of Securities.
|
Common Stock, par value $0.001 per share
699374302
5
If this statement is filed pursuant to Rule
13d-1(b),
or
13d-2(b),
check
whether the person filing is a:
|
|
|
|
|
(a)
|
|
☐
|
|
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
|
|
|
|
(b)
|
|
☐
|
|
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
|
|
|
|
(c)
|
|
☐
|
|
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
|
|
|
|
(d)
|
|
☐
|
|
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C.
80a-8).
|
|
|
|
(e)
|
|
☒
|
|
An investment advisor in accordance with
§240.13d-1(b)(1)(ii)(E).
|
|
|
|
(f)
|
|
☐
|
|
An employee benefit plan or endowment fund in accordance with
§240.13d-1(b)(1)(ii)(F).
|
|
|
|
(g)
|
|
☒
|
|
A parent holding company or control person in accordance with
§240.13d-1(b)(1)(ii)(G).
|
|
|
|
(h)
|
|
☐
|
|
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
|
|
|
|
(i)
|
|
☐
|
|
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C.
80a-3).
|
|
|
|
(j)
|
|
☐
|
|
Group, in accordance with
§240.13d-1(b)(1)(ii)(J).
|
|
(a)
|
As the investment manager of the HCM Fund, Highland Capital and Strand, as the general partner of Highland
Capital, may be deemed the beneficial owners of the 2,204,865 shares of Common Stock held by the HCM Fund.
|
Mr. Dondero may be deemed the beneficial owner of the 3,153,028 shares of Common Stock held by the Funds and the Trust.
|
(b)
|
Highland Capital and Strand may be deemed the beneficial owner of 6.9% of the outstanding Common Stock. This
percentage was determined by dividing 2,204,865, the number of shares of Common Stock held directly by the HCM Fund, by 32,140,977, which is the number of shares of Common Stock outstanding as of October 31, 2018 according to the Issuers
Quarterly Report on Form
10-Q
filed with the Securities Exchange Commission on November 6, 2018.
|
6
Mr. Dondero may be deemed the beneficial owner of 9.8% of the outstanding Common Stock.
This percentage was determined by dividing 3,153,028, the number of shares of Common Stock held directly by the Funds and the Trust, by 32,140,977, which is the number of shares of Common Stock outstanding as of October 31, 2018 according to
the Issuers Quarterly Report on Form
10-Q
filed with the Securities Exchange Commission on November 6, 2018.
|
(c)
|
Highland Capital and Strand have the shared power to vote and dispose of the 2,204,865 shares of Common Stock
held by the HCM Fund.
|
Mr. Dondero has the the shared power to vote and dispose of the 3,153,028 shares of Common
Stock held by the Funds and the Trust.
Item 5
|
Ownership of Five Percent or Less of a Class.
|
Inapplicable.
Item 6
|
Ownership of More Than Five Percent on Behalf of Another Person.
|
Inapplicable.
Item 7
|
Identification and Classification of the Subsidiary which Acquired the Security Being Reported On by the
Parent Holding Company.
|
Inapplicable.
Item 8
|
Identification and Classification of Members of the Group.
|
Inapplicable.
Item 9
|
Notice of Dissolution of Group.
|
Inapplicable.
By signing below each of the Reporting Persons certifies that, to the best of such persons knowledge and belief, the securities referred
to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction
having that purpose or effect.
7
|
|
|
Exhibits
|
|
Exhibit
99-1
|
|
|
|
|
Joint Filing Agreement, dated February 14, 2019, by and among Highland Capital, Strand and James D. Dondero.
|
8
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: February 14, 2019
|
|
|
|
|
HIGHLAND CAPITAL MANAGEMENT, L.P.
|
|
|
By:
|
|
Strand Advisors, Inc., its general partner
|
|
|
|
|
|
By:
|
|
/s/ James D. Dondero
|
|
|
|
|
Name: James D. Dondero
|
|
|
|
|
Title: President
|
|
STRAND ADVISORS, INC.
|
|
|
By:
|
|
/s/ James D. Dondero
|
Name: James D. Dondero
|
Title: President
|
|
/s/ James D. Dondero
|
James D. Dondero
|
.
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Apr 2023 to Apr 2024